Background: Cardiac-fatty acid binding-protein(C-FABP) is a potential marker for the early diagnosis of acute myocardial infarction (AMI), and is one of the abundant proteins in heart.It is not totally Heart bound and is also found in liver, skeletal muscle, kidney and brain.Over or under calculation of the levels of C-FABP is because of its simultaneous co-expression with hepatic-FABP and solely cardiac-FABP in brain. Due to the rising incidence of chronic liver diseases CLD among cardiac patients,serum markers may crossover and create confusions while making the diagnosis, so the aim of this study was to demarcate the behaviour of fundamental serum markers of both diseases, specially when the two diseases coexists simultaneously. Method: This study was carried at Union Hospital, Tongji Medical College,Wuhan,China over a period of about 1year from January2009 to January2010.A total of 100 patients were recruited. Study group included 50 patients with end stage chronic liver disease CLD, mean age 56.16±7.24 years.60%(n=30) were females.The control group included 50 participants who were healthy blood donors, mean age 61.34 ±9.76 years.Patients with cardiovascular complications like uncontrolled blood pressure, chronic ischaemic cardiomyopathies, cardiac cirrhosis, endocrine disorders, renal failure, ischaemic hepatitis and thyroid problems were excluded from the study. Serum levels of ALT,AST, Bilirubin and H-FABP were measured.Results were analyses statistically by using SPSS-12 and were compared by using ANOVA-Analysis.Significant results were indicated by probability values less than or equal to 0.05. Results: Only hepatic markers, Alanine aminotransferase ALT (196.37 ±127.8 Study group Vs 27.6 ±16.5 Control group, p < 0.0005) and serum Bilirubin(104.79 ±84.3 Study group Vs 10.4 ±3.6 Control group,p < 0.0001) were statistically significantly raised among study group in comparison to control group. There was no significant difference between the concentration of C-FABP in the study group and controls (6.54 ±2.8Study group Vs 6.88 ±2.4 Control group, p=NS). Conclusion: The concentration of C-FABP in those with liver disease was not statistically different from normal controls indicating that Liver-FABP (L-FABP) is a separate factor with negligible or no cross-reactivity with C-FABP assays. Measurement of C-FABP in the first 24 hours after onset of symptoms may be potentially useful for the diagnosis of Acute Myocardial Infarction in patients with chronic liver diseases.